# Questions, Answered — BPC-157, TB-500, and the Wolverine Blend

> Plain-language answers to the questions that recur about the BPC-157 and TB-500 research peptide pairing. Mechanism, dosing context, regulatory status, and the absence of a combination trial.

## What is the Wolverine peptide blend?

The Wolverine blend is a research-community nickname for a co-formulation of two synthetic peptides — BPC-157 and TB-500 — that researchers and athletes have paired in laboratory and forum contexts because their reported mechanisms touch tissue repair from complementary directions. The name describes a rapid-healing phenotype reported in rodent models, nothing more. It has no relationship to any character or property held by Marvel Entertainment, Marvel Comics, or The Walt Disney Company. The site uses the nickname once for orientation and otherwise refers to the pairing as the BPC-157 + TB-500 research blend [6][25].

## What are BPC-157 and TB-500, and why are they combined?

BPC-157 is a synthetic fifteen-amino-acid peptide modelled on a fragment of a cytoprotective protein found in human gastric juice [1]. TB-500, as sold by research-chemical suppliers, is the synthetic seven-amino-acid acetylated fragment Ac-LKKTETQ-OH, corresponding to the central actin-binding helix of the forty-three-amino-acid thymosin beta-4 [22]. They are combined in research and forum contexts because BPC-157 acts at the injury site through angiogenic and cytoprotective signalling [2][4] and TB-500 / Tβ4 acts inside the cell through actin sequestration and cell-migration regulation [9][10][22]. The mechanisms are largely non-overlapping; the rationale for combining them is mechanistic complementarity rather than a peer-reviewed combination study [6][25].

## Is TB-500 the same molecule as thymosin beta-4?

No. This is one of the most important distinctions on the site. TB-500 as sold by research-chemical suppliers is the synthetic seven-amino-acid fragment Ac-LKKTETQ-OH. Thymosin beta-4 (Tβ4) is the natural forty-three-amino-acid peptide, UniProt P62328. The fragment retains the central LKKTETQ actin-binding helix; it does not retain the rest of the chain [22]. The overwhelming majority of the human and clinical-grade preclinical efficacy data attributed to TB-500 in vendor literature — the RegeneRx / HLB corneal programme, the venous-stasis-ulcer Phase II, the Bock-Marquette cardiac work, the NL005 Phase I intravenous study — were generated with full-length Tβ4 [9][11][12][13][14][24]. Whether the fragment fully reproduces the full molecule's biology has not been formally demonstrated in head-to-head clinical work.

## How do BPC-157 and TB-500 work mechanistically?

BPC-157, in rodent and cell-culture work, upregulates VEGFR2-PI3K-Akt-eNOS angiogenic signalling at injury sites, modulates the nitric oxide system, increases growth-hormone-receptor expression in tendon fibroblasts (up to sevenfold in the Chang 2014 study), and shifts macrophage polarisation toward an anti-inflammatory M2 phenotype [2][4][20]. TB-500 / Tβ4 binds monomeric G-actin in one-to-one stoichiometry via its LKKTETQ helix, sequesters roughly forty to fifty percent of the cellular G-actin pool, activates integrin-linked kinase and Akt in cardiomyocytes (Bock-Marquette 2004), and mobilises epicardial and endothelial progenitor cells in adult mice (Smart 2007) [9][10][22]. The complementarity is the rationale for combining them; the combination itself has not been formally studied [6][25].

## Is there any peer-reviewed clinical trial on the BPC-157 + TB-500 combination?

No. Both the 2025 narrative review in Current Reviews in Musculoskeletal Medicine and the 2025 systematic review in HSS Journal note that no controlled head-to-head or combination study of BPC-157 and TB-500 has been published in a peer-reviewed journal that defines a synergy ratio, a combined dose, or a shared endpoint [6][7][25]. Synergy claims in commercial sources are mechanistic extrapolations.

## What is the FDA position on BPC-157 and TB-500?

In September 2023, the FDA placed both BPC-157 and Thymosin Beta-4 / TB-500 on its Category 2 list of bulk drug substances under section 503A — substances that may present significant safety risks. The Category 2 placement effectively excludes both from legal pharmacy compounding for human use in the United States. Neither compound is approved by the FDA for any indication, neither qualifies as a dietary supplement, and neither is a recognised drug or food additive [7].

## What is the WADA status of BPC-157 and TB-500?

BPC-157 is on the World Anti-Doping Agency Prohibited List under category S0 — non-approved substances — explicitly named on the 2022 list and on every annual list since, prohibited at all times in and out of competition. TB-500 / thymosin beta-4 is on the WADA Prohibited List under category S2 — peptide hormones, growth factors, related substances and mimetics — also prohibited at all times. A 2024 Canadian Centre for Ethics in Sport decision produced a four-year ineligibility for an athlete who used the combination.

## What doses appear in the BPC-157 research literature?

Most rodent studies use 10 μg/kg or 10 ng/kg by intraperitoneal injection, intragastric gavage, or in drinking water [1][3][4][8][21]. Some central-nervous-system studies use 200 μg/kg [20a]. The 2025 ischemia-reperfusion rat study used 20 μg/kg intraperitoneally [26]. He and colleagues' 2022 pharmacokinetic study used 20–500 μg/kg in rats and 6–150 μg/kg in beagle dogs by single intramuscular dose, and proposed an extrapolated human pilot dose of 200 μg/person/day [5]. None of these doses constitutes a recommendation for human use.

## What doses appear in the Tβ4 research literature?

For full-length Tβ4: preclinical doses range from 0.5–12 mg/kg by intraperitoneal injection in stroke and dermal-wound rodent models [17][16]. Bock-Marquette 2004 used 150 μg systemic plus 400 ng intracardiac in mice [9]. The NL005 Phase I in healthy human volunteers used 0.05–25 μg/kg single intravenous doses and 0.5–5 μg/kg/day intravenous for ten days [14]. The RGN-259 corneal programme used 0.01–0.1% topical ophthalmic solution up to six times daily [11][13][14a]. The dermal-wound Phase II programme used 0.01–0.1% topical gel once daily [12][16]. The seven-amino-acid TB-500 fragment has no published human dose-finding study.

## What is the half-life of BPC-157 and TB-500?

BPC-157 plasma half-life is under thirty minutes in rats and dogs after intramuscular dosing, per He and colleagues' 2022 study in Frontiers in Pharmacology [5]. Full-length Tβ4 shows dose-proportional pharmacokinetics with terminal half-life increasing at higher intravenous doses (NL005 Phase I); reported terminal half-life in healthy human volunteers is on the order of one to two hours at therapeutic doses [14]. The seven-amino-acid TB-500 fragment has no published human pharmacokinetic study; its half-life is presumed shorter than full-length Tβ4 because it lacks the chain extensions that contribute to plasma stability, but that presumption is not formally measured.

## What about the Phase II and Phase III data on Tβ4 in wound healing and the eye?

Guarnera and colleagues' multi-centre European Phase II of topical Tβ4 in seventy-two venous-stasis-ulcer patients reported an approximately one-month acceleration of wound closure and a clean safety profile [12]. Sosne and colleagues' fifty-six-day Phase II in severe dry eye disease reported a 35.1% reduction in ocular discomfort and a 59.1% reduction in corneal fluorescein staining versus vehicle at day 56 with the 0.1% RGN-259 ophthalmic solution [13]. A 2023 neurotrophic-keratopathy Phase III on RGN-259 met its healing and comfort endpoints, while the commercial SEER-3 Phase III at HLB Therapeutics missed its primary endpoint — Phase III evidence for the molecule is therefore mixed [14a][24].

## Why is the blend nicknamed "Wolverine" in the research community?

The nickname is descriptive — research-peptide forums adopted it as shorthand for the rapid-healing phenotype reported across the two compounds' independent rodent literatures. The nickname has no relationship to, affiliation with, endorsement by, or licence from Marvel Entertainment, Marvel Comics, The Walt Disney Company, or any related trademark holder. The site uses the term once for orientation in the title and otherwise prefers "BPC-157 + TB-500 research blend" or "regenerative peptide blend" as the primary descriptor.

## Is BPC-157 safe?

Jozwiak and colleagues' 2025 review in Pharmaceuticals records no observed teratogenic, genotoxic, anaphylactic, or local toxic effects at high doses in Sprague-Dawley rats (up to 20 mg/kg intramuscularly) or beagle dogs (up to 10 mg/kg intramuscularly), and flags two theoretical safety concerns — VEGFR2-mediated angiogenesis in malignant or pre-malignant tissue, and proline-derived reactive oxygen species — that have neither been demonstrated nor excluded in humans [20]. The published human BPC-157 record consists of three small uncontrolled reports from a single investigator group [6][25].

## Is Tβ4 safe?

The NL005 Phase I intravenous study in eighty-four healthy Chinese volunteers reported no dose-limiting toxicities and no serious adverse events across single doses of 0.05–25 μg/kg and multiple doses of 0.5–5 μg/kg/day for ten days [14]. The topical Tβ4 record across venous-stasis ulcer, dry-eye, and neurotrophic-keratopathy programmes reported consistent tolerability [12][13][14a]. Theoretical concerns about progenitor and endothelial cell mobilisation in tumour microenvironments have not been demonstrated and have not been excluded. The seven-amino-acid TB-500 fragment as marketed has no equivalent published human safety record.

## References

[1] Staresinic M, et al. BPC 157 — rat Achilles tendon. J Orthop Res. 2003;21(6):976-983.
[2] Chang CH, et al. BPC 157 — GH receptor in tendon fibroblasts. Molecules. 2014;19(11):19066-19077.
[3] Krivic A, et al. BPC 157 — tendon-to-bone healing. J Orthop Res. 2006;24(5):982-989.
[4] Brcic L, et al. BPC 157 — angiogenesis. J Physiol Pharmacol. 2009;60 Suppl 7:191-196.
[5] He L, et al. BPC 157 pharmacokinetics. Front Pharmacol. 2022;13:1026182.
[6] McGuire FP, et al. Regeneration or Risk? Curr Rev Musculoskelet Med. 2025;18(12):611-619.
[7] Vasireddi N, et al. Emerging Use of BPC-157. HSS Journal. 2025.
[8] Bajramagic S, et al. BPC 157 — intestinal anastomoses review. Pharmaceuticals. 2024;17(8):1081.
[9] Bock-Marquette I, et al. Thymosin beta4 — cardiac repair. Nature. 2004;432(7016):466-472.
[10] Smart N, et al. Thymosin β4 — epicardial progenitor mobilization. Nature. 2007;445(7124):177-182.
[11] Sosne G, et al. Thymosin beta 4 — corneal. Clin Ophthalmol. 2007;1(3):201-207.
[12] Guarnera G, et al. Thymosin beta-4 — venous ulcers. Ann N Y Acad Sci. 2007;1112:407-412.
[13] Sosne G, Dunn SP, Kim C. Thymosin β4 — dry eye Phase 2. Cornea. 2015;34(5):491-496.
[14] Wang T, et al. Phase I rhTβ4 NL005. J Cell Mol Med. 2021;25(18):8698-8708.
[14a] Sosne G, et al. RGN-259 — Phase III. IJMS. 2023;24(1):554.
[16] Kleinman HK, Sosne G. Thymosin β4 — dermal healing. Vitamins and Hormones. 2016;102:251-275.
[17] Santra M, et al. Thymosin β4 — oligodendrocyte differentiation. Glia. 2012;60(12):1826-1838.
[20] Jozwiak M, et al. BPC 157 — multifunctionality review. Pharmaceuticals. 2025;18(2):185.
[20a] Perovic D, et al. BPC 157 — spinal cord injury rats. J Orthop Surg Res. 2019;14(1):199.
[21] Matek D, et al. BPC 157 — rat quadriceps reattachment. Pharmaceutics. 2025;17(1):119.
[22] Safer D, Elzinga M, Nachmias VT. Thymosin β4 — actin sequestration. J Biol Chem. 1991;266(7):4029-4032.
[24] Sosne G, Kleinman HK. Thymosin beta 4 and the eye. Expert Opin Biol Ther. 2018;18(sup1):99-104.
[25] McGuire FP, et al. Regeneration or Risk? — combination commentary. Curr Rev Musculoskelet Med. 2025;18(12):611-619.
[26] Demirtas H, et al. BPC 157 — I/R protection. Medicina. 2025;61(2):291.

---

For research purposes only. Not for human consumption. This site does not sell any product and is not affiliated with any vendor.